γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO

  • Robert A. Koeth
  • , Bruce S. Levison
  • , Miranda K. Culley
  • , Jennifer A. Buffa
  • , Zeneng Wang
  • , Jill C. Gregory
  • , Elin Org
  • , Yuping Wu
  • , Lin Li
  • , Jonathan D. Smith
  • , W.H. Wilson Tang
  • , Joseph A. Didonato
  • , Aldons J. Lusis
  • , Stanley L. Hazen

Research output: Contribution to journalArticlepeer-review

497 Scopus citations

Abstract

L-carnitine, a nutrient in red meat, was recently reported to accelerate atherosclerosis via a metaorganismal pathway involving gut microbial trimethylamine (TMA) formation and host hepatic conversion into trimethylamine-N-oxide (TMAO). Herein, we show that following L-carnitine ingestion, γ-butyrobetaine (γBB) is produced as an intermediary metabolite by gut microbes at a site anatomically proximal to and at a rate ∼1,000-fold higher than the formation of TMA. Moreover, we show that γBB is the major gut microbial metabolite formed from dietary L-carnitine in mice, is converted into TMA and TMAO in a gut microbiota-dependent manner (like dietary L-carnitine), and accelerates atherosclerosis. Gut microbial composition and functional metabolic studies reveal that distinct taxa are associated with the production of γBB or TMA/TMAO from dietary L-carnitine. Moreover, despite their close structural similarity, chronic dietary exposure to L-carnitine or γBB promotes development of functionally distinct microbial communities optimized for the metabolism of L-carnitine or γBB, respectively.
Original languageEnglish
Pages (from-to)799-812
Number of pages14
JournalCell Metabolism
Volume20
Issue number5
DOIs
StatePublished - Nov 4 2014

Cite this